Jun 09, 2022 7:00am EDT Sonnet BioTherapeutics Announces Positive Results from a Preclinical Combination Study of SON-1010 with anti-PD1 Checkpoint Inhibition
Jun 02, 2022 9:25am EDT Sonnet BioTherapeutics Announces Adjournment of Annual Meeting Due to Lack of Quorum
May 10, 2022 8:15am EDT Sonnet BioTherapeutics Provides Fiscal Year 2022 Second Quarter Business and Earnings Update
Apr 13, 2022 7:00am EDT Sonnet BioTherapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of SON-1010 for Advanced Solid Tumors
Apr 08, 2022 1:05pm EDT Sonnet BioTherapeutics Announces Preclinical Data Supporting Its Bispecific Interleukin Candidates at the American Association for Cancer Research (AACR) 2022 Annual Meeting
Mar 16, 2022 7:00am EDT Sonnet BioTherapeutics Announces FDA Clearance of Its IND for SON-1010 for the Treatment of Advanced Solid Tumors
Feb 09, 2022 6:30am EST Sonnet BioTherapeutics Announces Abstract Accepted for Presentation in a Poster Session at the AACR 2022 Annual Meeting
Feb 08, 2022 7:00am EST Sonnet BioTherapeutics Provides Fiscal Year 2022 First Quarter Business and Earnings Update
Dec 17, 2021 6:30am EST Sonnet BioTherapeutics Provides Fiscal Year 2021 Business and Financial Update
Aug 30, 2021 4:01pm EDT Sonnet Announces Successful Completion of the Discovery Phase for Its Next Preclinical Pipeline Candidate (SON-1410)
